



OPEN

Synthetic mycobacterial diacyl trehaloses reveal differential recognition by human T cell receptors and the C-type lectin Mincle

Josephine F. Reijneveld^{1,2,3}, Mira Holzheimer³, David C. Young¹, Kattya Lopez^{1,4}, Sara Suliman¹, Judith Jimenez⁴, Roger Calderon⁴, Leonid Lecca⁴, Megan B. Murray⁵, Eri Ishikawa^{6,7}, Sho Yamasaki^{6,7}, Adriaan J. Minnaard³, D. Branch Moody¹ & Ildiko Van Rhijn^{1,2}✉

The cell wall of *Mycobacterium tuberculosis* is composed of diverse glycolipids which potentially interact with the human immune system. To overcome difficulties in obtaining pure compounds from bacterial extracts, we recently synthesized three forms of mycobacterial diacyltrehalose (DAT) that differ in their fatty acid composition, DAT₁, DAT₂, and DAT₃. To study the potential recognition of DATs by human T cells, we treated the lipid-binding antigen presenting molecule CD1b with synthetic DATs and looked for T cells that bound the complex. DAT₁- and DAT₂-treated CD1b tetramers were recognized by T cells, but DAT₃-treated CD1b tetramers were not. A T cell line derived using CD1b-DAT₂ tetramers showed that there is no cross-reactivity between DATs in an IFN- γ release assay, suggesting that the chemical structure of the fatty acid at the 3-position determines recognition by T cells. In contrast with the lack of recognition of DAT₃ by human T cells, DAT₃, but not DAT₁ or DAT₂, activates Mincle. Thus, we show that the mycobacterial lipid DAT can be both an antigen for T cells and an agonist for the innate Mincle receptor, and that small chemical differences determine recognition by different parts of the immune system.

Infection with *Mycobacterium tuberculosis* (Mtb) in humans elicits a T cell response. Detection of T cell responses to peptide antigens from Mtb, presented by major histocompatibility complex (MHC) proteins, forms the basis of the most reliable diagnostic assay for infection with Mtb¹. In addition to peptide antigens, cell wall lipids of Mtb have been shown to be presented by MHC class I-like proteins CD1a, CD1b, CD1c, and CD1d to T cells^{2–10}. The non-polymorphic nature of CD1 molecules makes lipids presented by CD1 proteins ideal targets for vaccine approaches and diagnostic purposes¹¹.

Among the many cell wall lipids of Mtb, some are present in most actinomycetes, whereas others exist among mycobacteria only, and some are strictly specific for the species Mtb. Mycobacterial lipids, such as mannosyl phosphomycoketide^{2,4}, phosphomycoketide⁶, glucose monomycolate⁵, mycolic acid⁸, glycerol monomycolate⁷, diacyl sulfoglycolipid (Ac₂SGL)⁹, and dideoxymycobactin³ have been shown to induce T cell responses via presentation by CD1 proteins. Contrary to the broad cross-reactivity against self and bacterial phospholipids^{12,13}, individual mycobacterial lipid-specific T cell clones show high specificity for the hydrophilic headgroup of Mtb

¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA 02115, USA. ²Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. ³Stratingh Institute for Chemistry, University of Groningen, Groningen, The Netherlands. ⁴Socios En Salud, Lima, Peru. ⁵Division of Global Health Equity, Department of Global Health and Social Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁶Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. ⁷Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan. ✉email: i.vanrhijn@uu.nl

lipids, while the hydrophobic parts of the lipid that are buried deep in the CD1 cleft are not typically recognized by the T cell receptor through direct contact¹⁴. Parts of the fatty acids that lie on the CD1 surface or sit near the antigen exit portal, might contribute to T cell recognition and specificity, especially when they show distinguishing features like double bonds, hydroxylations, and methylations.

Not all Mtb (glyco)lipids have been studied as T cell antigens. We propose that if a lipid binds sufficiently to a CD1 molecule, and it has clear features that distinguish it from common self-lipids like phospholipids and sphingolipids, it may be specifically recognized by T cells. Because CD1 interacts with lipid antigens via hydrophobic interactions, any glycolipid with one, two, or three hydrophobic tails and a suitable size might bind to CD1. One of these candidate lipids is diacyl trehalose (DAT). DAT is suggested to be part of the external surface of the mycobacterial cell wall¹⁵ and belongs to the family of trehalose-based glycolipids, which includes lipids such as Ac₂SGL. Although known as a biological substance for decades, DAT had not been chemically synthesized until recently¹⁶.

Besides functioning as lipid antigens for T cells, some mycobacterial lipids induce an innate response through pattern recognition receptors, such as the family of C-type lectin receptors (CLRs). The macrophage inducible Ca²⁺-dependent lectin (Mincle) receptor is one of the human CLRs. Trehalose-6,6'-dimycolate, a highly abundant glycolipid in the mycobacterial cell wall, was the first known Mtb lipid to activate the murine and human Mincle receptor¹⁷. Since then several natural and synthetic mycobacterial lipids have been shown to act as agonists for both the murine and human Mincle receptor, including DAT isolated from Mtb¹⁸. There has been growing interest in using Mincle ligands as adjuvants to promote a Th1 and Th17 immune response to subunit vaccines^{19,20}.

Here, we took advantage of precisely defined synthetic forms of DAT to discover receptor mediated human cellular responses. Three synthetic DATs were tested for their potential as Mincle and T cell receptor (TCR) ligands. We developed CD1b tetramers loaded with synthetic DAT to study recognition of DAT by T cells *ex vivo* in both healthy individuals and tuberculosis patients.

Results

Validation of synthetic diacyl trehalose. Natural DAT isolated from the cell wall of *M. tuberculosis* (Mtb) is a mixture of compounds that has immunomodulatory properties²¹. We recently synthesized three forms of DAT: DAT₁, DAT₂, and DAT₃, that differ in the fatty acyl unit esterified to the 3-position of the glucose moiety in trehalose, where DAT₁ carries mycosanoic acid, DAT₂ carries mycolipanic acid, and DAT₃ carries mycolipenic acid¹⁶. Synthetic DAT₁ and DAT₃ were previously demonstrated to be identical to natural products, but synthetic DAT₂ possessed identical fragmentation patterns to natural product, but did not co-elute by HPLC, suggesting that the two molecules are stereoisomers¹⁶. As a validation of the synthesized compound structure and quality after storage, high-performance liquid chromatography-mass spectrometry (HPLC-MS) analysis was performed (Fig. 1A–C). All three compounds yielded molecular ions with *m/z* values that, within experimental error, were consistent with the ammoniated synthesized target structures (*m/z* 948.735, 1006.776, and 988.766 for DAT₁, DAT₂, and DAT₃ respectively). Each synthetic compound gave a single major chromatographic peak, consistent with isomeric purity. Retention times in the reversed phase method are expected to increase with molecular size but decrease with increasing polarity of groups, such as the hydroxy group on the hydrocarbon chain, and the relative retention times of the synthetic DATs matched this prediction as DAT₂ was < DAT₁, with DAT₃ showing the longest retention time. Thus, the compounds showed high purity, correct mass and the expected retention times, allowing biological investigations of the antigenicity of DAT.

Diacyl trehalose acts as a Mincle ligand. Both natural mixed and synthetic forms of DAT can be ligands for macrophage-inducible C-type lectin (Mincle), a receptor of the innate immune system and activator of macrophages that responds to several types of trehalose containing glycolipids^{16,18}. To confirm that the stored synthetic lipids are bioactive, we tested their ability to activate Mincle by measuring the activation of NFAT-GFP in reporter cells expressing murine Mincle and its signaling subunit, the FcRγ chain. Synthetic DAT₃ acts as an agonist for Mincle, while stimulation of Mincle by DAT₁ and DAT₂ was not much higher than background even at the highest concentrations tested (Figs. 1D and S1), consistent with the previously reported pattern¹⁶. These results confirm that the chemical structure of DAT influences recognition by Mincle and that DAT₃ is a strong activator of Mincle.

Identification of CD1b-DAT tetramer-specific T cells. Regardless of their capacity to stimulate the innate immune system, it is possible that DAT₁, DAT₂, or DAT₃ can function as foreign lipid antigens presented by CD1 proteins for human T cells. Among human CD1 proteins, CD1b can present lipids with the longest and most alkyl chains²². The ~C42 forms of DAT studied here were somewhat larger than most lipids presenting by other CD1 isoforms, so we hypothesized that DAT could be presented by CD1b molecules to activate CD1b reactive T cells. To test this, we enriched T cells from healthy donor peripheral blood mononuclear cells (PBMCs) by depleting non-T cells using magnetic selection and stained them with CD1b tetramers that were treated with either synthetic DAT₁, synthetic DAT₂, or synthetic DAT₃. Some T cells recognize 'CD1b-endo' complexes, which are so named because they carry endogenous self-phospholipids from the mammalian CD1 protein expression system. Such T cells recognize CD1b-phospholipid or bind the CD1b protein itself independent of the lipid bound^{12,13}. Therefore, we stained the T cells simultaneously with a phycoerythrin (PE)-labeled synthetic DAT-treated CD1b tetramer and an allophycocyanin (APC)-labeled untreated CD1b tetramer (CD1b-endo). For quantification, residual non-T cells and auto-fluorescent cells were gated out, as well as CD1b-endo positive cells to determine true CD1b-DAT tetramer binding cells (Fig. S2a). CD1b-DAT tetramer⁺ cells were detected in all eight donors tested (Fig. 2A). Binding of CD1b-DAT₁ tetramers was the highest, with frequencies ranging from 0.031 to 0.007% of total T cells, followed by CD1b-DAT₂ (0.021–0.003%) and CD1b-DAT₃, which




Figure 1. Synthetic DAT is a Mincle ligand. Synthetic DAT₁ (A), DAT₂ (B), and DAT₃ (C) were analyzed by via high-performance liquid chromatography–mass spectrometry (HPLC–MS). Extracted ion chromatograms were generated for the ammoniated molecular ions. The mass spectra at the elution time of the ammoniated ions contained the expected molecular ions with H⁺, NH₄⁺, and Na⁺ adducts. Loss of hexose due to in-source fragmentation (calculated m/z 751.645 for DAT₁ and 791.676 for DAT₃) and sodium formate adduction with the Na⁺ adducted molecular ion (calculated m/z 1021.677 for DAT₁, 1079.719 for DAT₂, and 1061.708 for DAT₃) accounted for additional small peaks. Differences between the three forms of DAT are indicated in red in the structural formula, and the numbering of the trehalose carbons is shown in blue. (D) NFAT-GFP reporter cells expressing mouse Mincle + FcRγ were stimulated with the indicated amount of DAT₁, DAT₂, DAT₃, or TDM. After 24 h the induction of NFAT-GFP was analyzed by flow cytometry as shown in histogram and overlay flow cytometry histograms. Bar graphs represent three independent experiments. Values of each experiment are shown as symbols. Error bar represents standard deviation.

was the lowest (0.009–0.001%). Visualization of double staining of T cells with CD1b-DAT- and CD1b-endo tetramers, not gating CD1b-endo tetramer⁺ cells out (Fig. S2b), showed that most CD1b-DAT tetramer-binding cells fail to bind CD1b-endo, as illustrated by dot plots from donor 49 (Fig. 2B) or the other donors (Fig. S3). Together these results suggest that synthetic DAT₁ and synthetic DAT₂ are T cell antigens, while we could not convincingly detect CD1b-synthetic DAT₃ binding TCRs. Although we expect the three forms of DAT to load with comparable efficiency onto CD1b, we cannot formally exclude the possibility that DAT₃ was less efficiently loaded. Therefore, our inability to detect CD1b-DAT₃ binding T cells can be due to their absence in blood, or a failure to load tetramers with DAT₃.

To enable functional studies of T cell response, we stained PBMC from a healthy blood bank donor (HD1) with anti-CD3 and CD1b-synthetic DAT₂ tetramer. After two rounds of sorting and expansion of cells that were positive for CD3 and tetramer, we obtained an oligoclonal T cell line that, upon flow cytometric analysis, was demonstrated to consist mainly of T cells that stained double positive for mock treated CD1b (CD1b-mock) and CD1b-DAT₂ tetramer. The approximately 3% of the cells in the cell line that stained brightly with CD1b-DAT₂ tetramer but were negative for CD1b-mock tetramer were sorted and expanded further (Fig. 2C, third sort) to generate the 98% pure cell line HD1A (Fig. 2C, right panel). A 1.3% contamination of CD1b-mock⁺ cells was detected, which was not surprising because it formed the majority of the cells before the third sort. We further characterized line HD1A by staining with a panel of 24 Vβ antibodies (Fig. S4) and identified that it was an Vβ T cell line that stained with anti-Vβ13.2, which stains the TRBV6-2 gene product (Fig. 2D). Expression of TRBV6-2




Figure 2. Identification of CD1b-DAT binding human T cells. (A) Percentages of CD1b-DAT₁, -DAT₂, and -DAT₃ tetramer⁺ T cells of total T cells enriched from PBMC by column purification (n = 8 PBMC samples) are shown. (B) Flow cytometry dot plots show CD1b-endo, -DAT₁, -DAT₂, and -DAT₃ staining on T cells from one of the healthy donors. (C) A T cell line was generated by sorting peripheral blood mononuclear cells from Healthy Donor 1 (HD1) based on expression of CD3 and binding to CD1b tetramers treated with DAT₂ or mock treated (CD1b-mock), followed by expansion in vitro after each sort. Numbers next to or in the outlined red areas indicate percent cells in gate. (D) Flow cytometry dot plots show anti-CD1b- and anti-Vβ13.2 (TRBV6-2) staining on HD1A cell line. (E) TCR β chain sequence of HD1A TCR determined using a multiplex PCR and Sanger sequencing-based approach.

was confirmed by a multiplex PCR approach (Fig. 2E). Thus, we were able to detect CD1b-DAT tetramer-binding T cells ex vivo and derived a TRBV6-2⁺ synthetic DAT₂-specific αβT cell line.

Primary CD1b-DAT recognizing T cells show functional responses to antigen. For some CD1b-presented lipid antigens, the exact composition of the lipid tail does not matter for T cell recognition⁵. However, for other CD1b antigens, such as Ac₂SGL, mycolic acid, and mannosyl phosphomycoketide, the length and configuration of the acyl tail influences T cell activation^{2,23–25}. For these three lipids it was shown that differences in the structure of the acyl tails, such as length of the acyl chain and the number or pattern of C-methyl branched groups changes recognition by the TCR. We wondered whether the diversity in the acyl chains of the three synthesized DATs could influence recognition by T cells. Therefore, we asked whether T cell line HD1A that was sorted with CD1b-synthetic DAT₂ tetramers would be cross-reactive to the other synthetic DATs. Line HD1A, which stained strongly with CD1b tetramers treated with DAT₂, did not stain with DAT₁-treated tetram-




Figure 3. Line HD1A is reactive to DAT₂. (A) Flow cytometry histogram of line HD1A stained with DAT₁-, DAT₂-, or DAT₃-, or mock-treated CD1b tetramers (CD1b-mock). (B) IFN-γ ELISPOT of line HD1A stimulated with monocyte-derived dendritic cells treated with DAT₁, DAT₂, or DAT₃, with or without anti-CD1b antibody or Isotype control. Error bars represent standard error of the mean (SEM) of triplicate wells. One representative experiment of three is shown.

ers more than the background obtained with mock-treated tetramers (Fig. 3A). CD1b-DAT₃-treated tetramers showed a weak staining.

Tetramer staining suggests that the T cells would be responsive to the lipid antigen loaded onto the tetramers, but not all tetramer-binding T cells show functional responses upon presentation of antigen by antigen-presenting cells. To investigate functional responses to cellular presentation of synthetic DATs, we tested whether HD1A cells are functionally reactive to monocyte-derived dendritic cells, which represent in vitro generated primary APCs²⁶, treated with synthetic DATs. DAT₂ induced secretion of interferon-γ (IFN-γ) by HD1A T cells, while APCs treated with DAT₁, DAT₃ or medium alone, did not (Fig. 3B). Production of IFN-γ was almost completely blocked by anti-CD1b antibodies, indicating that CD1b is necessary for the activation of the HD1A by antigen, but not by other receptors present on the APCs, including CD1a, CD1c, or CD1d. Of note, synthetic DAT₃, which supported low CD1b tetramer staining, did not lead to IFN-γ responses, which is most likely due to low potency of DAT₃ as an antigen for HD1A. Thus, the HD1A cell line shows CD1b-dependent, highly specific functional responses to synthetic DAT₂ presented by APCs, which is likely caused by TCR recognition of the CD1b-DAT₂ complex. The lack of functional responses to DAT₁ and DAT₃ suggests that the chemical differences among DATs, consisting of the differing fatty acyl units at C3 of trehalose (Fig. 1A), influence recognition by T cells and prevents cross-reactivity.

CD1b-DAT₂ binding T cells in Peruvian cohort. Next, we wanted to measure the frequency of DAT₂-reactive T cells in a cohort of 150 human subjects^{27,28} to determine if there is an Mtb infection or disease-associated expansion of DAT-specific T cells. PBMCs were isolated from 50 Peruvian individuals with active

tuberculosis (TB) before the start of anti-TB drug treatment. In addition, PBMCs were isolated from 50 patients with latent TB infection and 50 household contacts with Mtb exposure, but no documented infection (uninfected), based on IFN- γ release assay results^{27,28}. To generate adequate numbers of T cells for the tetramer analysis, we expanded an aliquot of PBMCs by stimulation with anti-CD3 antibody and feeder cells, as previously described²⁸. CD1b-synthetic DAT₂ binding T cells were observed in subjects across all three groups, although in low frequencies. Comparing the median tetramer staining rate among the three groups based on TB disease status, the frequencies of CD1b-DAT₂ tetramer positive T cells did not significantly differ among active TB patients, latently infected patients, and uninfected subjects as determined by the Kruskal-Wallis test (Fig. 4A). Staining patterns of expanded PBMCs with CD1b-synthetic DAT₂ vary from broad smear of tetramer positive cells as illustrated by three subjects with tetramer-binding T cells (subjects 115-7, 149-4, and 63-1) to smaller high affinity populations, as seen for subject 206-0 (Fig. 4B). Thus, synthetic DAT₂ is recognized by T cells in the blood, but frequencies of these cells did not increase after infection with Mtb.

Discussion

Here we have characterized the antigenicity of DAT for the human immune system and show that synthetic DATs are able to act as both an innate and an adaptive agonist. Small differences in chemical structure between the three synthetic forms of DAT had strong effects on stimulation of innate versus adaptive receptors. We determined that DAT₃, but not DAT₁ or DAT₂, behaved as a highly potent activator of the innate receptor Mincle, while DAT₁ was by far the most potent compound recognized by polyclonal, ex-vivo T cells across multiple donors.

As predicted, DAT could be presented by CD1b and act as an antigen for T cells. Across multiple healthy donors we observed T cell binding to CD1b-DAT tetramers with frequencies similar to binding of CD1b-GMM and mycolic acid tetramers²⁸. The highest percentage of CD1b-DAT tetramer⁺ cells was observed using synthetic DAT₁ treated tetramers, followed by synthetic DAT₂ treated CD1b tetramers, while the percentage CD1b-synthetic DAT₃ tetramer⁺ T cells was extremely low. These results suggest that the composition of methyl-branched fatty acids of DAT strongly influences recognition by CD1b-reactive T cells.

Among the trehalose-based glycolipids that are made by Mtb, DAT is one of the smallest and simplest. Whereas sulfoglycolipids are sulfated on the 2'-position of the trehalose core and can carry up to four alkyl chains⁹, DAT is not sulfated and by definition carries two alkyl chains¹⁶. DAT carries an esterified unbranched saturated fatty acid on the 2-position of trehalose and a branched fatty acid on the 3-position: mycosanoic (DAT₁), mycolipanic (DAT₂) or mycolipenic acid (DAT₃)¹⁶. Thus, although sulfoglycolipids can carry longer and more complex branched fatty acids at the 2- and 3-position, Ac₂SGL is the closest relative of DAT. The binding mechanism of Ac₂SGL to CD1b is known and shows that CD1b presents Ac₂SGL to T cells with the participation of endogenous spacer lipid that is simultaneously bound in the cleft²⁹. The presence of these spacers in addition to Ac₂SGL leads to rearrangement of the lipid-binding groove, allowing accommodation for bulky antigens. At the same time this rearrangement reduces the capacity of the A' pocket of CD1b to accommodate the phthioceranyl chain of Ac₂SGL, forcing the first three methyl groups of the fatty acyl chain to remain exposed above the CD1b surface for recognition by TCR²⁹. Since Ac₂SGL and DAT show structural similarities, DAT might be presented by CD1b in a similar way, with the methyl branched motif exposed on the outer surface of CD1b. If that is true, differences in the exposed residues that are available for TCR recognition, such as the presence of the extra hydroxy group in the acyl chain of DAT₂ and the α,β -unsaturation in DAT₃, might explain the observed lack of cross-recognition by TCRs, such as HD1A. In addition, the differences in the number of C-methyl groups on the fatty acid of DAT₁ (2 groups) and DAT₂ and DAT₃ (3 groups) could play a role in lack of cross-reactivity. However, the opposite effect was observed for Ac₂SGL: an increased number of methyl-branched carbons led to an increase in the ability of the synthetic Ac₂SGLs to stimulate T cells, which was true for up to four methyl groups²⁴. Thus, the nature of the effect of methyl-branched fatty acids of DAT on T cell recognition by CD1b-reactive T cells can only be fully understood by additional analyses, including protein crystallography of the trimolecular complex of CD1b-DAT-TCR.

The Peruvian TB cohort data shows that synthetic DAT₂ is recognized by T cells in people with active TB, healthy latently Mtb-infected, and uninfected controls. However, a difference in frequencies of CD1b-DAT binding T cells among highly exposed groups that differed in their IGRA status was not observed, similar to other CD1b tetramer studies in cohorts^{28,30}. Also, the range of percentage of CD1b-DAT₂ tetramer⁺ T cells of Peruvian subjects was similar to the Boston healthy donors. Together, these data suggest that CD1b-DAT₂-specific T cells do not expand upon Mtb exposure, or, if they do, it is not detectable among T cells that circulate in the blood. Recent studies have suggested that total blood MR1-reactive T cells can stay unchanged or fall in the setting of infection or antigen-stimulation^{27,31–33}. Thus, a more general perspective to emerge from these studies is that blood-based quantification is not a reliable measure of total body T cell dynamics. Nevertheless, these studies provide proof of principle for DAT specific T cells response and point to DAT₁ as the T cell antigen with highest response.

In conclusion, our results show that the mycobacterial lipid DAT is an antigen for T cells as well as a stimulating ligand for the Mincle receptor, but the structural differences in the fatty acyl chains of the different forms of DAT strongly influence the type of biological response they elicit.

Material and methods

HPLC-MS of synthetic DAT. Diacyl trehaloses were synthesized as previously published (13). The synthetic DAT compounds were analyzed on an Agilent Technologies 6530 Accurate-Mass Q-TOF HPLC-MS system. Reversed phase liquid chromatography (LC) used a C-18 HPLC column (Agilent Poroshell 120, 2.7 mm, 4.6 mm \times 100 mm) and a gradient method with 7:3 methanol:water (solvent A) and 85:15 1-propanol:cyclohexane (solvent B). Both solvents contained 2.0 mM ammonium formate. 0.1% water was added to solvent B to aid dissolution. The solvent gradient used a 0.5 mL/min flowrate throughout and started at 60% solvent B, increased




Figure 4. Quantification of CD1b-DAT₂ tetramer binding T cells in a Peruvian TB cohort. **(A)** Frequencies of CD1b-mock and CD1b-DAT₂ tetramer⁺ T cells among the 150 subjects of the Peruvian cohort, analyzed by TB disease status. Medians and interquartile ranges of tetramer⁺ T cells are depicted as a percent of total CD3⁺ cells. **(B)** Representative flow cytometry dot plots from subjects with CD1b-DAT₂ tetramer positive T cells.

linearly starting at 1.0 min and ending at 100% solvent B at 10.0 min, and finally holding at 100% B until 15.0 min. Runs were initiated with 10 μL injections of the synthetic compounds at a concentration of 20 ng/mL in starting mobile phase. Detected ions were analyzed using Agilent Technologies MassHunter Qualitative Analysis B.07.00 software.

Mincle activation assay. For the cellular Mincle assays DAT₁, DAT₂, and DAT₃ were dissolved in chloroform/methanol at 1 mg/mL, diluted in isopropanol to appropriate concentrations and added to a 96-well plate at 20 μL /well. After evaporation of the isopropanol, 30,000 2B4-NFAT-GFP reporter cells expressing mouse Mincle were added to each well in 100 μL medium. After incubation at 37 °C for 24 h the expression of NFAT-GFP was analyzed by flow cytometry.

Human subjects. The Brigham and Women's Hospital Specimen Bank, Boston, provided de-identified leukoreduction filters from local blood bank donors for PBMC isolation. Subjects with pulmonary TB disease and their household contacts were recruited through Socios En Salud, an affiliate of Partners in Health, based in Lima, Peru^{27,28}. We enrolled 50 patients with culture confirmed pulmonary TB and 100 of their asymptomatic household contacts of whom 50 had positive IGRA tests, as determined by the QuantiFERON TB-Gold In-Tube assay (Qiagen) and 50 subjects were IGRA negative (classified as "exposed but uninfected"). Participants were at least 14 years old and had a negative HIV serology test. Peripheral blood mononuclear cells (PBMC) were isolated from 50 mL of blood and cryopreserved at 5×10^6 cells per aliquot. The Institutional Review Board of the Harvard Faculty of Medicine and Partners Healthcare, and the Institutional Committee of Ethics in Research of the Peruvian Institutes of Health approved this study protocol. All adult study participants and parents or legal guardians of minors had to provide informed consent, while minors provided assent. All methods were performed in accordance with the relevant guidelines and regulations.

Tetramers. For lipid loading, WT CD1b monomers were obtained from the NIH tetramer facility. In a 10 mm wide glass tube, 16 μg of dry lipid was sonicated at 37 °C for 1 h in 45 μL of 0.5% CHAPS 50 mM sodium citrate buffer pH 4.5 for DAT-treated tetramers, as previously described for other lipid ligands²⁸. For CD1b-mock no lipid was added to the tube. Subsequently, CD1b monomers (10 μg) were added to the tubes and incubated overnight at 37 °C. The next day the solution of the monomers was neutralized to pH 7.4 by adding 5 μL 1 M Tris pH 8. Monomers were tetramerized using streptavidin-APC (Molecular Probes) or streptavidin-PE (Invitrogen).

T cell lines and T cell assays. For generation of T cell lines, total PBMC or PBMC-derived T cells were stained with CD1b-DAT tetramer and anti-CD3. PBMCs were sorted for double positive staining of CD3 and tetramer. Expansion of sorted cells was performed by plating cells at 100–700 cells/well in round-bottom 96-well plates containing 2.5×10^5 irradiated allogeneic PBMCs, 5×10^4 irradiated Epstein Barr Virus transformed B cells, and 30 ng/mL anti-CD3 antibody (clone OKT3) per plate as described previously²⁸. The next day human IL-2 was added to the wells. After 2 weeks, sorting and expansion procedure was repeated as needed. For ELISPOT assays, cocultures of 4×10^4 APCs (G4 monocytes) pre-incubated with DAT for 30 min 37 °C and 1×10^3 T cells were incubated for 16 h in a Multiscreen-IP filter plate (96 wells; Millipore) coated according to the manufacturer's instructions (Mabtech). For blocking, APCs were preincubated for 1 h at 37 °C with anti-CD1b blocking antibody BCD1b3.1 or control IgG P3 (10 $\mu\text{g}/\text{mL}$) before adding T cells.

Staining protocol. T cells were enriched by depletion of non-T cells using the Pan T cell Isolation Kit (Miltenyi Biotec) according to manufacturer's protocol. Human enriched T cells and T-cell lines were stained with tetramers at 2 $\mu\text{g}/\text{mL}$ in PBS containing 1% BSA and 0.01% sodium azide. Cells and tetramer were incubated for 10 min at room temperature in the dark, followed by addition of cell surface antibodies for 10 min at room temperature as described previously^{27,28}. Subsequently, cells were treated with unlabeled OKT3 antibody and incubated for 20 min at 4 °C. Cells were analyzed using the BD LSRFortessa flow cytometer and FlowJo software. For staining of PBMCs from Peruvian participants $\sim 3 \times 10^6$ cells were stained with a "live-dead" fixable blue cell stain (Molecular Probes), then treated with tetramer in for 10 min at room temperature, followed by cell surface antibodies for 5 min. Subsequently, cells were treated with unlabeled OKT3 antibody and incubated for 5 min at room temperature, followed by 10 min at 4 °C. Cells were fixed in fresh 2% paraformaldehyde (Electron Microscopy Sciences) in PBS for 20 min. Antibodies that were used: CD3-BV421 (UCHT1; Biolegend), CD3-FITC (SK7; BD Bioscience).

TCR sequencing. TCR sequences were determined by isolating RNA from bulk sorted T cell populations using the RNeasy kit (QIAGEN), followed by complementary DNA synthesis using the QuantiTect Reverse Transcription Kit (QIAGEN). TCR transcripts were amplified using a multiplex approach¹², followed by direct Sanger sequencing of the PCR product.

Received: 21 October 2020; Accepted: 4 January 2021
Published online: 21 January 2021

References

- Pai, M. *et al.* Gamma interferon release assays for detection of *Mycobacterium tuberculosis* infection. *Clin. Microbiol. Rev.* **27**, 3–20 (2014).
- de Jong, A. *et al.* CD1c presentation of synthetic glycolipid antigens with foreign alkyl branching motifs. *Chem. Biol.* **14**, 1232–1242 (2007).
- Moody, D. B. *et al.* T cell activation by lipopeptide antigens. *Science* **303**, 527–531 (2004).
- Moody, D. B. *et al.* CD1c-mediated T-cell recognition of isoprenoid glycolipids in *Mycobacterium tuberculosis* infection. *Nature* **404**, 884–888 (2000).
- Moody, D. B. *et al.* Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. *Science* **278**, 283–286 (1997).
- Ly, D. *et al.* CD1c tetramers detect ex vivo T cell responses to processed phosphomycolate antigens. *J. Exp. Med.* **210**, 729–741 (2013).
- Layre, E. *et al.* Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. *Chem. Biol.* **16**, 82–92 (2009).
- Beckman, E. M. *et al.* Recognition of a lipid antigen by CD1-restricted $\alpha\beta$ + T cells. *Nature* **372**, 691–694 (1994).
- Gilleron, M. *et al.* Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with *Mycobacterium tuberculosis*. *J. Exp. Med.* **199**, 649–659 (2004).
- Sieling, P. A. *et al.* CD1-restricted T cell recognition of microbial lipoglycan antigens. *Science* **269**, 227–230 (1995).
- Van Rhijn, I. & Moody, D. B. Donor unrestricted T cells: a shared human T cell response. *J. Immunol.* **195**, 1927–1932 (2015).
- Shahine, A. *et al.* A T-cell receptor escape channel allows broad T-cell response to CD1b and membrane phospholipids. *Nat. Commun.* **10**, 1–12 (2019).
- Van Rhijn, I. *et al.* Human autoreactive T cells recognize CD1b and phospholipids. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 380–385 (2016).
- Gras, S. *et al.* T cell receptor recognition of CD1b presenting a mycobacterial glycolipid. *Nat. Commun.* **7**, 13257 (2016).
- Ortalo-Magné, A. *et al.* Identification of the surface-exposed lipids on the cell envelopes of *Mycobacterium tuberculosis* and other mycobacterial species. *J. Bacteriol.* **178**, 456–461 (1996).
- Holzheimer, M. *et al.* Asymmetric total synthesis of mycobacterial diacyl trehaloses demonstrates a role for lipid structure in immunogenicity. *ACS Chem. Biol.* **15**, 1835–1841 (2020).
- Ishikawa, E. *et al.* Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. *J. Exp. Med.* **206**, 2879–2888 (2009).
- Decout, A. *et al.* Rational design of adjuvants targeting the C-type lectin Mincle. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 2675–2680 (2017).
- Lang, R., Schoenen, H. & Desel, C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions. *Immunobiology* **216**, 1184–1191 (2011).
- Schoenen, H. *et al.* Cutting Edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. *J. Immunol.* **184**, 2756–2760 (2010).
- Lee, K. *et al.* Diacyltrehalose of *Mycobacterium tuberculosis* inhibits lipopolysaccharide- and mycobacteria-induced proinflammatory cytokine production in human monocytic cells. *FEMS Microbiol. Lett.* **267**, 121–128 (2007).
- Moody, D. B. *et al.* Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. *Nat. Immunol.* **3**, 435–442 (2002).
- Gau, B. *et al.* Simplified deoxypropionate acyl chains for *mycobacterium tuberculosis* sulfoglycolipid analogues: chain length is essential for high antigenicity. *ChemBioChem* **14**, 2413–2417 (2013).
- Guiard, J. *et al.* Fatty acyl structures of *mycobacterium tuberculosis* sulfoglycolipid govern T cell response1. *J. Immunol.* **182**, 7030–7037 (2009).
- Van Rhijn, I. *et al.* CD1b-mycolic acid tetramers demonstrate T-cell fine specificity for mycobacterial lipid tails. *Eur. J. Immunol.* **47**, 1525–1534 (2017).
- Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α . *J. Immunol.* **200**, 887–896 (2018).
- Suliman, S. *et al.* Peripheral blood mucosal-associated invariant T (MAIT) cells in tuberculosis patients and healthy *Mycobacterium tuberculosis*-exposed controls. *J. Infect. Dis.* **222**, 995–1007 (2020).
- Lopez, K. *et al.* CD1b Tetramers broadly detect T cells that correlate with mycobacterial exposure but not tuberculosis disease state. *Front. Immunol.* **11**, 199 (2020).
- Garcia-Alles, L. F. *et al.* Structural reorganization of the antigen-binding groove of human CD1b for presentation of mycobacterial sulfoglycolipids. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 17755–17760 (2011).
- Layton, E. D. *et al.* Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination. *J. Immunol. Methods* **458**, 44–52 (2018).
- Le Bourhis, L. *et al.* Antimicrobial activity of mucosal-associated invariant T cells. *Nat. Immunol.* **11**, 701–708 (2010).
- Jiang, J. *et al.* Mucosal-associated invariant T cells from patients with tuberculosis exhibit impaired immune response. *J. Infect.* **72**, 338–352 (2016).
- Kwon, Y. *et al.* Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. *Tuberculosis* **95**, 267–274 (2015).

Acknowledgements

DBM was supported by National Institutes of Health (NIH) grant R01 AI049313. DBM, MM, and IVR were supported by and NIH Tuberculosis Research Unit Network, Grant U19 AI112224. JFR, MH, and AJM were supported by Nederlands Wetenschappelijk Onderzoek (NWO) Toppunt grant 15.002.

Author contributions

J.F.R. and I.V.R. designed research. J.F.R., S.S., I.V.R., K.L. and D.Y. performed experiments. M.H., A.J.M., E.I., S.Y., J.J., R.C., M.M., and L.L. contributed unique reagents. J.F.R., D.Y., D.B.M., and I.V.R. analyzed data. J.F.R., D.B.M., and I.V.R. wrote the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-81474-3>.

Correspondence and requests for materials should be addressed to I.V.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021